Sativex nabiximols: Phase III data

Top-line data from a double-blind, international Phase III trial in 399 patients with advanced cancer who experienced inadequate analgesia during optimized chronic opioid therapy showed that

Read the full 262 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE